GO:0003070 regulation of systemic arterial blood pressure by neurotransmitter: Neurogenic Blood Pressure Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003070 describes the biological process in which neurotransmitters released from presynaptic neurons regulate systemic arterial blood pressure.
• The autonomic nervous system, especially sympathetic noradrenergic outflow, is the principal mediator of rapid, neurotransmitter-driven blood pressure control.
• Acetylcholine, norepinephrine, nitric oxide and other neurotransmitters act on vascular smooth muscle, endothelium and cardiac tissue to modulate vascular tone and cardiac output.
• Dysregulation of neurotransmitter-mediated blood pressure control contributes to hypertension, neurogenic pulmonary edema, and cerebrovascular disease.
• Cholinergic enhancement via choline acetyltransferase administration lowers blood pressure in murine hypertension, demonstrating a therapeutic axis within this GO term.
• CRISPR knockout, knock-in, point-mutation and overexpression models are essential for dissecting the causal roles of neurotransmitter pathway genes in blood pressure regulation.
Description
GO:0003070, regulation of systemic arterial blood pressure by neurotransmitter, is a biological process term that captures how neurotransmitters released from presynaptic neurons modulate systemic arterial blood pressure. This process is fundamental to cardiovascular homeostasis, integrating rapid neural signals with vascular and cardiac effectors to maintain adequate tissue perfusion. Unlike slower humoral or renal mechanisms of blood pressure control, neurotransmitter-mediated regulation operates on a timescale of seconds to minutes, making it critical for beat-to-beat adaptation to posture, stress and exercise. The autonomic nervous system provides the anatomical substrate for this process, with sympathetic and parasympathetic divisions releasing norepinephrine, acetylcholine and co-transmitters onto target cells in blood vessels and the heart. For researchers, GO:0003070 provides a precise ontological framework for annotating genes and pathways that link neuronal signaling to arterial pressure. The term encompasses neurotransmitter synthesis, vesicular release, receptor activation, second-messenger signaling and downstream effects on vascular smooth muscle tone and cardiac output. Disruption of these steps is implicated in human disease: neurogenic pulmonary edema is a dramatic example of sympathetic neurotransmitter surge causing pulmonary and systemic hemodynamic failure, while impaired cerebrovascular regulation by phenylephrine highlights the clinical relevance of adrenergic signaling in the brain. Understanding GO:0003070 also matters for therapeutic development. Choline acetyltransferase administration reduces blood pressure in murine hypertension, showing that augmenting cholinergic neurotransmitter pathways can counteract hypertensive states. Nitric oxide, a gaseous neurotransmitter and signaling molecule, participates in both central and peripheral blood pressure regulation. Thus, GO:0003070 sits at the intersection of neuroscience, cardiovascular physiology and translational medicine, and is a high-value target for functional genomics and CRISPR-based interrogation.
regulation of systemic arterial blood pressure by neurotransmitter At A Glance
| GO ID | GO:0003070 |
|---|---|
| GO term | regulation of systemic arterial blood pressure by neurotransmitter |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Neurotransmitter-mediated modulation of systemic arterial blood pressure |
| Definition source | QuickGO definition: regulation of blood pressure mediated by a neurotransmitter |
| Key neurotransmitters | Norepinephrine, acetylcholine, nitric oxide, phenylephrine (agonist), and related molecules |
| Primary anatomical systems | Autonomic nervous system, vascular smooth muscle, endothelium, heart |
| Related disease examples | Hypertension, neurogenic pulmonary edema, cerebrovascular dysregulation |
What Is GO:0003070?
GO:0003070 is defined by QuickGO as the regulation of blood pressure mediated by a neurotransmitter. A neurotransmitter is any of a group of substances that are released on excitation from the axon terminal of a presynaptic neuron of the central or peripheral nervous system and travel across the synaptic cleft to either excite or inhibit the target cell. In practical terms, this process covers all molecular and cellular events through which neuronally released chemicals alter systemic arterial blood pressure, including neurotransmitter biosynthesis, release, receptor binding, signal transduction and effector responses in the cardiovascular system.
Why Is regulation of systemic arterial blood pressure by neurotransmitter Important in Cell Biology?
GO:0003070 is important because it defines the fastest and most plastic mechanism by which the body controls arterial blood pressure, and its dysfunction underlies acute and chronic cardiovascular pathology. The autonomic nervous system continuously adjusts vascular tone and cardiac output through neurotransmitter release, and failure of this regulation can produce hypertensive crisis, neurogenic pulmonary edema, or inadequate cerebral perfusion. Because neurotransmitter pathways are druggable and genetically tractable, this GO term guides both mechanistic research and therapeutic target discovery, as shown by cholinergic interventions that lower blood pressure in murine hypertension.
• Provides the ontological basis for annotating genes involved in rapid neural control of blood pressure.
• Central to understanding sympathetic and parasympathetic contributions to hypertension and hypotension.
• Explains the pathophysiology of neurogenic pulmonary edema, a life-threatening sympathetic surge syndrome.
• Relevant to cerebrovascular regulation, where adrenergic agents such as phenylephrine alter cerebral blood flow.
• Nitric oxide, a neurotransmitter-like mediator, is a key regulator of vascular tone and blood pressure.
• Cholinergic enhancement via choline acetyltransferase reduces blood pressure in murine hypertension.
• Guides CRISPR-based functional studies of neurotransmitter synthesis, release and receptor genes.
• Supports drug discovery targeting adrenergic and cholinergic receptors for cardiovascular disease.
• Links neuroscience and cardiovascular physiology, enabling cross-disciplinary research.
• Provides a framework for interpreting genetic variants in neurotransmitter pathway genes in blood pressure regulation.
What Happens During regulation of systemic arterial blood pressure by neurotransmitter?
Neurotransmitter synthesis and vesicular packaging in presynaptic neurons
In simple terms: Neurons make chemical messengers and pack them into tiny bubbles for release.
The process begins with the synthesis of neurotransmitters such as norepinephrine and acetylcholine in presynaptic neurons of the autonomic nervous system. These molecules are packaged into synaptic vesicles and transported to axon terminals, ready for release upon excitation. The anatomical organization of the autonomic nervous system ensures that sympathetic and parasympathetic neurons innervate blood vessels and the heart, positioning them to regulate systemic arterial blood pressure.
Excitation-release coupling and synaptic cleft transmission
In simple terms: When a neuron fires, it squirts messenger chemicals across a tiny gap to the next cell.
Upon excitation, neurotransmitters are released from the axon terminal into the synaptic cleft, where they travel to excite or inhibit target cells. This release is calcium-dependent and tightly regulated, allowing rapid adjustments in vascular tone and cardiac function. The synaptic cleft acts as a diffusion barrier and signaling space, ensuring that neurotransmitters act locally on specific receptors.
Receptor activation on vascular smooth muscle and endothelium
In simple terms: The messenger chemicals dock onto receptors on blood vessel cells, telling them to tighten or relax.
Neurotransmitters bind to adrenergic, cholinergic and other receptors on vascular smooth muscle and endothelial cells. Activation of these receptors triggers second-messenger cascades that alter intracellular calcium and contractile machinery, thereby changing vascular diameter and systemic vascular resistance. Nitric oxide, a gaseous mediator, can also act on vascular smooth muscle to promote vasodilation and modulate blood pressure.
Cardiac effects and integrated systemic arterial pressure response
In simple terms: The same messengers also tell the heart how fast and hard to pump, changing blood pressure.
Neurotransmitters also act on the heart, altering heart rate and contractility, which together with vascular changes determine cardiac output and systemic arterial blood pressure. Sympathetic activation generally increases heart rate and contractility, while parasympathetic activation slows the heart. The integration of vascular and cardiac effects produces the final systemic arterial blood pressure response, which can be measured experimentally using techniques such as laser Doppler flowmetry and translational cerebrovascular monitoring.
Pathophysiological amplification: neurogenic pulmonary edema and hypertensive states
In simple terms: When the nervous system overfires, blood pressure can spike dangerously and damage organs.
Massive sympathetic neurotransmitter release can cause neurogenic pulmonary edema, characterized by pulmonary and systemic hemodynamic instability. In chronic hypertension, altered neurotransmitter signaling contributes to sustained high blood pressure, and interventions that enhance cholinergic transmission can lower blood pressure in murine models. These pathophysiological states highlight the clinical importance of GO:0003070 and provide experimental paradigms for studying its components.
Key Genes Involved in GO:0003070 regulation of systemic arterial blood pressure by neurotransmitter
The following genes and proteins are central to neurotransmitter-mediated regulation of systemic arterial blood pressure, based on their established roles in autonomic signaling, vascular tone and cardiac function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TH | Tyrosine hydroxylase, rate-limiting enzyme in norepinephrine synthesis | Target for knockout and point-mutation studies of sympathetic tone |
| DBH | Dopamine beta-hydroxylase, converts dopamine to norepinephrine | Genetic models of noradrenergic dysfunction and blood pressure |
| CHAT | Choline acetyltransferase, synthesizes acetylcholine | Overexpression lowers blood pressure in murine hypertension |
| SLC18A2 | Vesicular monoamine transporter 2, packages monoamines into vesicles | Knockout models for impaired neurotransmitter release |
| ADRA1A | Alpha-1A adrenergic receptor, mediates vasoconstriction | Point-mutation and knock-in studies of adrenergic signaling |
| ADRB1 | Beta-1 adrenergic receptor, mediates cardiac chronotropy and inotropy | Knockout models for heart rate and blood pressure regulation |
| CHRM2 | Muscarinic acetylcholine receptor M2, mediates parasympathetic cardiac effects | Knock-in and knockout studies of cholinergic control |
| NOS1 | Neuronal nitric oxide synthase, produces nitric oxide | Knockout models for nitrergic blood pressure regulation |
| NOS3 | Endothelial nitric oxide synthase, produces nitric oxide in endothelium | Overexpression and point-mutation studies of vascular tone |
| GCH1 | GTP cyclohydrolase 1, cofactor synthesis for catecholamine and nitric oxide synthases | Knockout models for neurotransmitter synthesis defects |
| SLC6A2 | Norepinephrine transporter, reuptakes norepinephrine | Knockout and point-mutation studies of synaptic norepinephrine |
| PNMT | Phenylethanolamine N-methyltransferase, converts norepinephrine to epinephrine | Genetic models of adrenergic tone |
| AGTR1 | Angiotensin II receptor type 1, modulates sympathetic activity | Knock-in models for neurohumoral blood pressure control |
| ACE | Angiotensin-converting enzyme, influences sympathetic outflow | Knockout models for blood pressure regulation |
| CAV1 | Caveolin-1, regulates vascular signaling and nitric oxide | Knockout models for arterial dysfunction |
| CAVIN1 | Cavin-1, caveolar structural protein | Deficiency causes arterial dysfunction with maintained systemic blood pressure |
| P2RX4 | Purinergic receptor, mediates ATP neurotransmitter effects | Knockout models for purinergic vascular control |
How Is regulation of systemic arterial blood pressure by neurotransmitter Regulated?
The process of neurotransmitter-mediated blood pressure regulation is itself regulated at multiple levels. Presynaptic autoreceptors and reuptake transporters control the amount of neurotransmitter available in the synaptic cleft, thereby modulating signal strength. Nitric oxide can act as a retrograde messenger and modulator of neurotransmitter release and vascular tone. Cholinergic and adrenergic signaling are reciprocally regulated, and enhancing cholinergic activity via choline acetyltransferase can lower blood pressure in hypertensive states. Additionally, caveolar proteins such as cavin-1 influence arterial function and systemic blood pressure, indicating that membrane microdomain organization regulates neurotransmitter signaling components.
regulation of systemic arterial blood pressure by neurotransmitter and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CHAT | Hypertension | Overexpression in murine hypertension |
| ADRA1A | Cerebrovascular dysregulation | Point-mutation knock-in for receptor sensitivity |
| NOS1 | Vascular dysfunction | Knockout for nitrergic signaling |
| CAVIN1 | Arterial dysfunction | Knockout mouse with maintained blood pressure |
| TH | Sympathetic overactivity | Conditional knockout for catecholamine synthesis |
Hypertension and neurogenic blood pressure elevation
Excessive sympathetic neurotransmitter release and impaired cholinergic counter-regulation contribute to hypertension. Choline acetyltransferase administration reduces blood pressure in murine hypertension, demonstrating that shifting the autonomic balance toward cholinergic signaling can counteract hypertensive mechanisms. Genetic and pharmacological studies of adrenergic receptors and transporters are therefore central to hypertension research within GO:0003070.
Neurogenic pulmonary edema
Neurogenic pulmonary edema is a life-threatening condition caused by massive sympathetic discharge, leading to pulmonary and systemic hemodynamic failure. This disorder exemplifies the pathological consequences of unchecked neurotransmitter-mediated blood pressure regulation and provides a clinical context for studying GO:0003070.
Cerebrovascular dysregulation
Adrenergic agents such as phenylephrine alter cerebrovascular regulation, and impaired neurotransmitter-mediated control can compromise cerebral perfusion. Translational studies of phenylephrine effects on cerebrovascular regulation highlight the importance of adrenergic signaling in maintaining brain blood flow.
Arterial dysfunction and vascular disease
Deficiency in cavin-1 causes arterial dysfunction despite maintained systemic blood pressure, indicating that structural and signaling components of vascular cells intersect with neurotransmitter-mediated regulation. Nitric oxide dysfunction is also implicated in vascular injury and systemic inflammation.
From regulation of systemic arterial blood pressure by neurotransmitter-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TH reduce neurotransmitter-mediated blood pressure regulation? | TH knockout or conditional knockout |
| Does a point mutation in ADRA1A alter vascular response to phenylephrine? | ADRA1A point-mutation knock-in |
| Can CHAT overexpression lower blood pressure in hypertension? | CHAT overexpression in murine hypertension |
| How does tagged NOS1 affect nitric oxide signaling in vivo? | Tagged NOS1 knock-in for imaging and proteomics |
| Does CAVIN1 deficiency cause arterial dysfunction? | CAVIN1 knockout mouse |
| What is the effect of SLC6A2 knockout on synaptic norepinephrine? | SLC6A2 knockout |
How to Study the regulation of systemic arterial blood pressure by neurotransmitter Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Tail-cuff plethysmography | Systemic arterial blood pressure | Hypertension models |
| Laser Doppler flowmetry | Regional blood flow | Pulpal blood flow regulation |
| Transcranial Doppler | Cerebral blood flow velocity | Cerebrovascular regulation by phenylephrine |
| HPLC/mass spectrometry | Neurotransmitter concentrations | Tissue catecholamine and acetylcholine levels |
| Fluorescent NO probes | Nitric oxide production | Vascular signaling studies |
| Immunoblotting | Protein expression and modification | Caveolar protein analysis |
| CRISPR knockout | Gene function loss | Causal testing of neurotransmitter genes |
| Knock-in/overexpression | Gain-of-function or tagged protein | CHAT overexpression, tagged NOS1 |
Hemodynamic and blood pressure measurements
Systemic arterial blood pressure can be measured directly via arterial catheters or indirectly via tail-cuff plethysmography in animal models. Laser Doppler flowmetry has been used to assess arterial blood pressure regulation of pulpal blood flow, demonstrating the sensitivity of regional perfusion to systemic pressure changes. Translational cerebrovascular regulation studies using phenylephrine provide protocols for assessing adrenergic effects on cerebral blood flow.
Genetic and pharmacological manipulation
Knockout, knock-in and overexpression models allow causal testing of neurotransmitter pathway genes. For example, choline acetyltransferase administration lowers blood pressure in murine hypertension, establishing a gain-of-function paradigm. Pharmacological agents such as phenylephrine are used to probe adrenergic contributions to cerebrovascular regulation.
Molecular and biochemical assays
Neurotransmitter levels can be quantified by HPLC or mass spectrometry, while receptor activation can be assessed by second-messenger assays. Nitric oxide production can be measured using fluorescent probes or by quantifying nitrite/nitrate. Caveolar protein function can be studied by immunoblotting and co-immunoprecipitation in cavin-1-deficient models.
Imaging and functional readouts
Laser Doppler flowmetry and other imaging modalities allow real-time assessment of vascular responses to neurotransmitters. Cerebrovascular regulation can be monitored using translational approaches such as transcranial Doppler or MRI-based perfusion imaging. These methods link molecular events to integrated systemic arterial blood pressure outcomes.
How CRISPR Can Be Used to Study GO:0003070 regulation of systemic arterial blood pressure by neurotransmitter
Knockout
CRISPR knockout is used to delete genes such as TH, DBH, CHAT, SLC6A2 and NOS1 to determine their causal roles in neurotransmitter-mediated blood pressure regulation. Knockout models can reveal whether loss of a specific neurotransmitter pathway component alters baseline blood pressure or responses to pharmacological challenges.
Point Mutation
Point-mutation knock-in can model human variants in adrenergic or cholinergic receptors, such as ADRA1A, to test altered ligand sensitivity and downstream vascular responses. These models are valuable for precision medicine approaches to blood pressure disorders.
Knock-in
Knock-in of tagged proteins, such as fluorescently labeled NOS1 or CHAT, enables real-time imaging and proteomic analysis of neurotransmitter signaling components in vivo. Knock-in can also be used to humanize specific genes for drug testing.
Overexpression
Overexpression of CHAT via viral or transgenic approaches lowers blood pressure in murine hypertension, demonstrating the therapeutic potential of enhancing cholinergic neurotransmitter pathways. Overexpression models are also used to study gain-of-function effects of adrenergic receptors or nitric oxide synthases.
How EDITGENE Supports regulation of systemic arterial blood pressure by neurotransmitter Research
Researchers studying regulation of systemic arterial blood pressure by neurotransmitter-related genes often need to determine whether a candidate gene is causally involved in blood pressure control, and CRISPR-based models provide the most direct way to establish causality. EDITGENE offers a comprehensive suite of gene editing and screening services tailored to this GO term.
Contact EDITGENE today to design your custom CRISPR model for regulation of systemic arterial blood pressure by neurotransmitter research.
Frequently Asked Questions About regulation of systemic arterial blood pressure by neurotransmitter
What is GO:0003070?
GO:0003070 is the biological process term for regulation of systemic arterial blood pressure by neurotransmitter, defined as the regulation of blood pressure mediated by a neurotransmitter released from presynaptic neurons.
What genes are involved in regulation of systemic arterial blood pressure by neurotransmitter?
Key genes include TH, DBH, CHAT, SLC18A2, ADRA1A, ADRB1, CHRM2, NOS1, NOS3, SLC6A2 and CAVIN1, among others.
How does the autonomic nervous system regulate blood pressure?
The autonomic nervous system releases neurotransmitters such as norepinephrine and acetylcholine onto blood vessels and the heart, adjusting vascular tone and cardiac output to control systemic arterial blood pressure.
What is the role of nitric oxide in blood pressure regulation?
Nitric oxide acts as a signaling molecule and neurotransmitter that promotes vasodilation and modulates vascular tone, contributing to systemic blood pressure regulation.
Can cholinergic signaling lower blood pressure?
Yes, systemic administration of choline acetyltransferase decreases blood pressure in murine hypertension, indicating that enhancing cholinergic neurotransmission can lower blood pressure.
What is neurogenic pulmonary edema?
Neurogenic pulmonary edema is a condition caused by massive sympathetic discharge, leading to pulmonary and systemic hemodynamic failure, and is a pathological example of neurotransmitter-mediated blood pressure dysregulation.
How is cerebrovascular regulation affected by adrenergic agents?
Phenylephrine, an alpha-adrenergic agonist, affects cerebrovascular regulation, and translational studies help define its impact on cerebral blood flow.
What experimental models are used to study GO:0003070?
Common models include knockout mice for neurotransmitter synthesis genes, knock-in mice for receptor point mutations, and overexpression models for cholinergic enzymes.
What is the role of cavin-1 in arterial function?
Cavin-1 deficiency causes arterial dysfunction but maintained systemic blood pressure, indicating a role in vascular signaling that intersects with neurotransmitter regulation.
How can CRISPR help study neurotransmitter-mediated blood pressure regulation?
CRISPR knockout, knock-in, point-mutation and overexpression models allow causal testing of specific genes in neurotransmitter pathways and their effects on blood pressure.
Conclusion
GO:0003070, regulation of systemic arterial blood pressure by neurotransmitter, is a vital biological process that integrates neuronal signaling with cardiovascular effectors to control blood pressure on a rapid timescale. Its components are implicated in hypertension, neurogenic pulmonary edema and cerebrovascular dysregulation, making it a rich area for mechanistic and translational research. CRISPR-based functional genomics, combined with hemodynamic and molecular assays, offers powerful tools to dissect this process and identify new therapeutic targets. EDITGENE provides end-to-end support for researchers investigating this GO term, from knockout and knock-in model generation to library screening and bioinformatics.
References
- 1. Waxenbaum JA et al.. 2026. Anatomy, Autonomic Nervous System.. PMID: 30969667
- 2. Simon RP. 1993. Neurogenic pulmonary edema.. Neurol Clin 11(2):309-23 PMID: 8316188
- 3. Stiegler A et al.. 2021. Systemic administration of choline acetyltransferase decreases blood pressure in murine hypertension.. Mol Med 27(1):133 PMID: 34674633
- 4. Martínez-Caro L et al.. 2015. Inhibition of Nitro-Oxidative Stress Attenuates Pulmonary and Systemic Injury Induced by High-Tidal Volume Mechanical Ventilation.. Shock 44(1):36-43 PMID: 25895143
- 5. Sasano T et al.. 1989. Arterial blood pressure regulation of pulpal blood flow as determined by laser Doppler.. J Dent Res 68(5):791-5 PMID: 2654230
- 6. Luchkanych AMS et al.. 2025. Effect of Phenylephrine on Cerebrovascular Regulation: A Translational Perspective.. J Am Heart Assoc 14(19):e042396 PMID: 40996064
- 7. Rovira I. 1995. [Nitric oxide].. Rev Esp Anestesiol Reanim 42(1):15-23 PMID: 7892526
- 8. Swärd K et al.. 2014. Arterial dysfunction but maintained systemic blood pressure in cavin-1-deficient mice.. PLoS One 9(3):e92428 PMID: 24658465
